Target values in hypertension treatment. Will they apply in older patients with hypertension, diabetics and in patients with IHD?

Czech version

Authors: J. Widimský
Authors‘ workplace: Klinika kardiologie IKEM Praha, přednosta prof. MUDr. Jan Kautzner, CSc., FESC
Published in: Vnitř Lék 2009; 55(9): 833-840
Category: 80th Birthday - prof. MUDr. Miloš Štejfa, DrSc., FESC

Overview

The incidence of isolated systolic hypertension increases with age since 50 years. Systolic pressure appears to have higher prognostic importance than diastolic pressure in patients older than 50 years. Treatment of isolated systolic hypertension importantly decreases cerebrovascular events, coronary events as well as overall mortality. Studies providing the relevant evidence have mostly been conducted at the beginning of 1990s. The baseline systolic pressure in all these studies was 160 mmHg and higher. This is because the isolated systolic hypertension then was defined as systolic pressure of 160 mmHg or higher and diastolic hypertension as pressure of 95 mmHg or higher. No study confirming that systolic pressure lowering to the range of 140–159 mmHg in older patients would positively affect morbidity and mortality, with a further aim to achieve systolic pressure levels of less than 140 mmHg, have been conducted so far. The recommendation to aim, even in older patients, for the target values of less than140 mmHg is based mainly on observational studies. Possible existence of the diastolic pressure Ј-curve in patients with ischemic heart disease represents another unresolved issue. There is a lack of randomised studies on this subject comparing reduction of the diastolic pressure to below 80, below 70 mmHg and below 60 mmHg. The joint guidelines of the European Society of Hypertension and European Society of Cardiology recommend the target value of <140/90 mmHg for the treatment of isolated systolic hypertension, and systolic pressure of less than 130 mmHg in patients with diabetes, cardiovascular or renal diseases (following myocardial infarction, cerebrovascular event or renal dysfunction), in patients with metabolic syndrome and in patients with the overall cardiovascular SCORE-based risk of ≥ 5%. There are no data available confirming that lowering blood pressure to these target values is justified. The ‘lower the blood pressure is better’ rule applies to cerebrovascular events only. The data from the large ONTARGET study show that lowering of the systolic blood pressure to less than130 mmHg does not bring any benefit to hypertonics with high cardiovascular risk, except from cerebrovascular events. The J-curve exists for cardiovascular mortality, myocardial infarction and probably also for diabetics, with the turning point at about 130 mmHg. Further reduction of blood pressure increases cardiovascular mortality and myocardial infarctions. We believe that, in the current atmosphere of contradictory data on the diastolic pressure and coronary events relationship J-curve, caution is needed in older patients with isolated systolic hypertension and IHD in cases when the on-treatment diastolic pressure falls below 70 mmHg. In such a situation we would not insist on reaching the systolic pressure target value. We believe that this should apply to older patients with ischemic heart disease in particular. In summary, it is possible to conclude that hypertension treatment target blood pressure values of less than 140/90 mmHg are justified. However, target values of less than 130/80 mmHg in diabetics, in patients with a cardiovascular disease and in other patient groups (metabolic syndrome, overall cardiovascular risk of 5% or higher) are challenged by the results of a range of large studies, and verification in prospective studies is of utmost importance.

Key words:
BP target values – systolic and diastolic pressure J-curve

Sources

1. National High Blood Pressure Education Program Working Group. National High Blood Pressure Education Program working group report on hypertension in the elderly. Hypertension 1994; 23: 275–285.

2. Psaty BM, Furberg CD, Kuller LH et al. Association between blood pressure level and the risk of myocardial infarction, stroke, and total mortality. Arch Intern Med 2001; 161: 1183–1192.

3. Williams B, Lindholm L, Sever P. Systolic pressure is all that matters. Lancet 2008; 371: 2219–2221.

4. Mancia G, De Backer G, Dominiczak A et al. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 Guidelines for the management of arterial hypertension. J Hypertens 2007; 25: 1105–1187.

5. Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J Hypertens 2009; 27: 923–934.

6. Lewington S, Clarke R, Qizilbash N et al. Prospective Studies Collaborators. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903–1913.

7. PROGRESS Colalborative Group. Randomised trial of perindopril-based blood-pressure-lowering regimen among 6.105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–1041.

8. Arima H, Chalmers J, Woodward M et al. PROGRESS Collaborative Group. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens 2006; 24: 1201–1208.

9. Yusuf S, Sleight P, Pogue J et al. The Heart Outcomes Prevention Evaluation (HOPE) Investigation. Effects of an angiotensin converting enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med 2000; 342: 145–153.

10. Fox KM. EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease; randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003, 362: 782–788.

11. Bosch J, Yusuf S, Pogue J et al. HOPE Investigators. Use of ramipril in preventing stroke: double blind randomised trial. Br Med J 2002; 324: 699–702.

12. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in MICROHOPE substudy. Lancet 2000; 355: 253–259.

13. Estacio RO, Jeffers BW, Gifford N et al. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000; 23 (Suppl 2): B54–B64.

14. Patel A, MacMahon S, Chalmers J et al. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829–840.

15. Sleight P, Redon J, Verdecchia P et al. ONTARGET investigators. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens 2009; 27: 1360–1369.

16. Cushman WC, Grimm RH Jr, Cutler JA et al. ACCORD Study Group. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007; 99 (Suppl 1): 44i–55i.

17. Julius S, Kjeldsen SE, Weber M et al. VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022–2031.

18. Jamerson K, Weber MA, Bakris GL et al. ACCOMPLISH Trial Investigators. Benazepril plus Amlodipin or Hydrochlorothiazid for Hypertension in High Risk Patients. N Engl J Med 2008; 359: 2417–2428.

19. Franklin SS, Jacobs MJ, Wong ND et al. Predominance of isolated systolic hypertension among moderately aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES III). Hypertension 2001; 37: 869–874.

20. Beckett NS, Peters R, Fletcher AE et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887–1898.

21. Farnett L, Mulrow CD, Linn WD et al. The J-curve phenomenon and the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous? JAMA 1991; 265: 489–495.

22. Somes GW, Pahor M, Shorr RI et al. The role of diastolic blood pressure when treating isolated systolic hypertension. Arch Intern Med 1999; 159: 2004–2009.

23. Staessen J, Bulpitt C, Clement D et al. Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the elderly. Br Med J 1989; 298: 1552–1556.

24. Boutitie F, Gueyffier F, Pocock S et al. J-shaped relationship between blood pressure and mortality in hypertensive patients: new insights from a meta-analysis of individual-patient data. Ann Intern Med 2002; 136: 438–448.

25. Nissen SE, Tuzcu EM, Libby P et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. The CAMELOT Study: A randomized controlled trial. JAMA 2004; 292: 2217–2225.

26. Sipahi I, Tuzcu EM, Schoenhagen P et al. Effects of normal, pre-hypertensive, and hypertensive blood pressure levels on progression of coronary atherosclerosis. J Am Coll Cardiol 2006; 48: 833–838.

27. Chhatrivalla AK, Nicholls SJ, Wang TH et al. Low levels of low-density lipoprotein cholesterol and blood pressure and progression of coronary atherosclerosis. J Am Coll Cardiol 2009; 53: 1110–1115.

28. Tobis JM, Perlowski A. Atheroma volume by intravascular ultrasound as a surrogate for clinical end points. J Am Coll Cardiol 2009; 53: 1116–1118.

29. Messerli FH, Mancia G, Conti R et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006; 144: 884–893.

30. Pepine CJ, Handberg EM, Cooper-DeHoff RM et al. INVEST Investigators. A calcium antagonist vs. non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil SR/Trandolapril Study (INVEST): A randomized controlled trial. JAMA 2003; 290: 2805–2816.

31. Messerli FH, Mancia G, Weber MA et al. Low blood pressure is associated with increased cardiovascular morbidity (J-shaped curve) in treated hypertensive patients with increased cardiovascular risk: The VALUE Randomized Trial. Proceedings from the 58th Annual Scientific Session of the American College of Cardiology, Orlando, March 29-April 1, 2009. J Am Coll Cardiol 2009; 53 (Suppl A): A46.

32. Bangalore S, Messerli FH, Wun CC et al. J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) trial. Am Soc Hypertens 2009; San Francisco CA: Poster 177.

33. LaRosa JC, Grundy SM, Waters DD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425–1435.

34. Kaplan NM. Kaplan’s Clinical Hypertension. 9th ed. Philadelphia: Lippincott Williams & Wilkins 2006.

35. Mancia G. Přednáška na 19. kongresu o hypertenzi. Milán 12.–16. června 2009.